- Conditions
- Schizophrenia
- Interventions
- sodium nitroprusside, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 62
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Smoking Cessation
- Interventions
- Novolin R
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 21 Years to 40 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Kidney Disease
- Interventions
- Sodium bicarbonate, Placebos
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Atezolizumab, Bevacizumab, Capecitabine, Laboratory Biomarker Analysis, Placebo
- Drug · Biological · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 614
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
- Conditions
- Larynx Disease
- Interventions
- Lansoprazole Tablet, PH and impedence testing, manometry, lansoprazole, placebo
- Drug · Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Durvalumab, Nintedanib, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Onychomycosis
- Interventions
- terbinafine, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 20
- States / cities
- Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
- Conditions
- Intestinal Gas
- Interventions
- Charcocaps, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Memphis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acne Vulgaris
- Interventions
- DMT310, Hydrogen Peroxide, Placebo
- Drug
- Lead sponsor
- Dermata Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- San Diego, California • Saint Joseph, Missouri • Henderson, Nevada + 6 more
- Conditions
- SARS-CoV-2
- Interventions
- Upamostat, Placebo (PO)
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- Drug · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Covid19, Coronavirus Infection, SARS-CoV-2 Infection
- Interventions
- 0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide, 0.075% Cetylpyridinium Chloride
- Other · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Tube Feeding
- Interventions
- Methylnaltrexone, Saline injection
- Drug
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Onychomycosis/Onycholysis and Tinea Pedis
- Interventions
- Placebo, Terbinafine Hydrochloride, Terbinafine
- Drug
- Lead sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Paramus, New Jersey
- Conditions
- Acne Vulgaris
- Interventions
- DMT310, Placebo
- Drug
- Lead sponsor
- Dermata Therapeutics
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Freemont, California • Austin, Texas
- Conditions
- Stroke, Ischemic
- Interventions
- Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
- Drug · Other
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Digestive Health, Gastrointestinal Health, FODMAP Intolerance, Food Sensitivity
- Interventions
- Fructanase, Maltodextrin placebo
- Dietary Supplement
- Lead sponsor
- BIO-CAT, Inc.
- Industry
- Eligibility
- 20 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Addison, Illinois
- Conditions
- Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
- Interventions
- Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
- Drug · Other · Procedure
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Healthy
- Interventions
- Ambrotose LIFE, Advanced Ambrotose, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Memphis
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Parkinson's Disease
- Interventions
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 301 participants
- Timeline
- 2002 – 2003
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more
- Conditions
- Onychomycosis
- Interventions
- terbinafine, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
- Biological · Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more